Advanced Vaccine Design Strategies Against SARS-CoV-2 and Emerging Variants

Overview

Journal Bioengineering (Basel)

Date 2023 Feb 25

PMID 36829642

Authors

Jianzhong Zhang

Yutian Xia

Xuan Liu

Gang Liu

Affiliations

Soon will be listed here.

Abstract

Vaccination is the most cost-effective means in the fight against infectious diseases. Various kinds of vaccines have been developed since the outbreak of COVID-19, some of which have been approved for clinical application. Though vaccines available achieved partial success in protecting vaccinated subjects from infection or hospitalization, numerous efforts are still needed to end the global pandemic, especially in the case of emerging new variants. Safe and efficient vaccines are the key elements to stop the pandemic from attacking the world now; novel and evolving vaccine technologies are urged in the course of fighting (re)-emerging infectious diseases. Advances in biotechnology offered the progress of vaccinology in the past few years, and lots of innovative approaches have been applied to the vaccine design during the ongoing pandemic. In this review, we summarize the state-of-the-art vaccine strategies involved in controlling the transmission of SARS-CoV-2 and its variants. In addition, challenges and future directions for rational vaccine design are discussed.

Citing Articles

Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety.

Malek E, Fallah Mehrabadi M, Es-Haghi A, Nofeli M, Mokaram A, Moradi M Heliyon. 2024; 10(22):e40124.

PMID: 39584086 PMC: 11585676. DOI: 10.1016/j.heliyon.2024.e40124.

Improving the last mile delivery of vaccines through an informed push model: Experiences, opportunities and costs based on an implementation study in a rural district in Uganda.

Bakkabulindi P, Wafula S, Ssebagereka A, Sekibira R, Mutebi A, Ameny J PLOS Glob Public Health. 2024; 4(10):e0002647.

PMID: 39466730 PMC: 11515991. DOI: 10.1371/journal.pgph.0002647.

Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre-Fusion Spike Glycoproteins Protects Non-Human Primates against SARS-CoV-2 Infection.

Wang S, Qin M, Xu L, Mu T, Zhao P, Sun B Vaccines (Basel). 2023; 11(9).

PMID: 37766104 PMC: 10535855. DOI: 10.3390/vaccines11091427.

The COVID-19 Pandemic: How Technology Is Reshaping Public Health and Medicine.

Coelho L, Glotsos D, Reis S Bioengineering (Basel). 2023; 10(5).

PMID: 37237681 PMC: 10215714. DOI: 10.3390/bioengineering10050611.

References

Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L . Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 2020; 588(7838):498-502. PMC: 7116492. DOI: 10.1038/s41586-020-2665-2. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Sun S, Cai Y, Song T, Pu Y, Cheng L, Xu H . Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021; 31(9):1011-1023. PMC: 8280646. DOI: 10.1038/s41422-021-00531-8. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Zang J, Zhu Y, Zhou Y, Gu C, Yi Y, Wang S . Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. Cell Discov. 2021; 7(1):71. PMC: 8372230. DOI: 10.1038/s41421-021-00315-9. View

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

Patone M, Mei X, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M . Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022; 146(10):743-754. PMC: 9439633. DOI: 10.1161/CIRCULATIONAHA.122.059970. View

Collier D, Ferreira I, Kotagiri P, Datir R, Lim E, Touizer E . Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021; 596(7872):417-422. PMC: 8373615. DOI: 10.1038/s41586-021-03739-1. View

Cohen A, van Doremalen N, Greaney A, Andersen H, Sharma A, Starr T . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. 2022; 377(6606):eabq0839. PMC: 9273039. DOI: 10.1126/science.abq0839. View

10.

Troyano-Hernaez P, Reinosa R, Holguin A . Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week. Viruses. 2021; 13(2). PMC: 7913946. DOI: 10.3390/v13020243. View

11.

Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C . Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine. 2022; 45:101323. PMC: 8903824. DOI: 10.1016/j.eclinm.2022.101323. View

12.

Pallesen J, Wang N, Corbett K, Wrapp D, Kirchdoerfer R, Turner H . Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114(35):E7348-E7357. PMC: 5584442. DOI: 10.1073/pnas.1707304114. View

13.

Schmidt A, Lapuente D . T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine. Viruses. 2021; 13(2). PMC: 7911237. DOI: 10.3390/v13020199. View

14.

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

15.

He W, Zhang W, Yan H, Xu H, Xie Y, Wu Q . Distribution and evolution of H1N1 influenza A viruses with adamantanes-resistant mutations worldwide from 1918 to 2019. J Med Virol. 2020; 93(6):3473-3483. DOI: 10.1002/jmv.26670. View

16.

He Q, Mao Q, An C, Zhang J, Gao F, Bian L . Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021; 10(1):629-637. PMC: 8009122. DOI: 10.1080/22221751.2021.1902245. View

17.

Pan J, Wang Y, Cao L, Wang Y, Zhao Q, Tang S . Impact of immunization programs on 11 childhood vaccine-preventable diseases in China: 1950-2018. Innovation (Camb). 2021; 2(2):100113. PMC: 8454656. DOI: 10.1016/j.xinn.2021.100113. View

18.

Derking R, Sanders R . Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. J Int AIDS Soc. 2021; 24 Suppl 7:e25797. PMC: 8606863. DOI: 10.1002/jia2.25797. View

19.

Sanchez-Felipe L, Vercruysse T, Sharma S, Ma J, Lemmens V, Van Looveren D . A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature. 2020; 590(7845):320-325. DOI: 10.1038/s41586-020-3035-9. View

20.

Guerrera G, Picozza M, DOrso S, Placido R, Pirronello M, Verdiani A . BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Sci Immunol. 2021; 6(66):eabl5344. DOI: 10.1126/sciimmunol.abl5344. View